Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Blueprint Medicines (NASDAQ: BPMC) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Monday, April 7, 2025, at 12:45 p.m. ET.

Investors and interested parties can access a live webcast of the presentation through Blueprint Medicines' website's Investors & Media section. The presentation recording will remain accessible on the company's website for 30 days following the event.

News Market Reaction – BPMC

-0.24%

1 alert

-0.24% News Effect

On the day this news was published, BPMC declined 0.24%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24^th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET.

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-24th-annual-needham-virtual-healthcare-conference-302411391.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines (BPMC) presenting at the Needham Healthcare Conference 2025?

Blueprint Medicines will present on Monday, April 7, 2025, at 12:45 p.m. ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch Blueprint Medicines' (BPMC) Needham Conference presentation?

Investors can watch the live webcast through Blueprint Medicines' website at ir.blueprintmedicines.com in the Investors & Media section.

How long will BPMC's Needham Conference presentation replay be available?

The webcast replay will be archived on Blueprint Medicines' website for 30 days after the presentation.

What type of presentation will BPMC deliver at the 2025 Needham Healthcare Conference?

Blueprint Medicines management will participate in a fireside chat format presentation.